MX2021000107A - Formas sólidas de 2-(3,5-dicloro-4-((5-isopropil-6-oxo-1,6-dihidro piridazin-3-il)oxi)fenil)-3,5-dioxo-2,3,4,5-tetrahidro-1,2,4-tria zin-6-carbonitrilo. - Google Patents
Formas sólidas de 2-(3,5-dicloro-4-((5-isopropil-6-oxo-1,6-dihidro piridazin-3-il)oxi)fenil)-3,5-dioxo-2,3,4,5-tetrahidro-1,2,4-tria zin-6-carbonitrilo.Info
- Publication number
- MX2021000107A MX2021000107A MX2021000107A MX2021000107A MX2021000107A MX 2021000107 A MX2021000107 A MX 2021000107A MX 2021000107 A MX2021000107 A MX 2021000107A MX 2021000107 A MX2021000107 A MX 2021000107A MX 2021000107 A MX2021000107 A MX 2021000107A
- Authority
- MX
- Mexico
- Prior art keywords
- carbonitrile
- dioxo
- tetrahydro
- dichloro
- oxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862692914P | 2018-07-02 | 2018-07-02 | |
| PCT/US2019/040276 WO2020010068A1 (en) | 2018-07-02 | 2019-07-02 | Solid forms of 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021000107A true MX2021000107A (es) | 2021-05-27 |
Family
ID=67441642
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021000107A MX2021000107A (es) | 2018-07-02 | 2019-07-02 | Formas sólidas de 2-(3,5-dicloro-4-((5-isopropil-6-oxo-1,6-dihidro piridazin-3-il)oxi)fenil)-3,5-dioxo-2,3,4,5-tetrahidro-1,2,4-tria zin-6-carbonitrilo. |
| MX2024013198A MX2024013198A (es) | 2018-07-02 | 2021-01-06 | Formas solidas de 2-(3,5-dicloro-4-( (5-isopropil-6-oxo -1,6-dihidropiridazin-3-il) oxi) fenil)-3,5-dioxo -2,3,4,5-tetrahidro -1,2,4-triazina-6-carbonitrilo |
| MX2023009701A MX2023009701A (es) | 2018-07-02 | 2021-01-06 | Formas solidas de 2-(3,5-dicloro-4-( (5-isopropil-6-oxo -1,6-dihidropiridazin-3-il) oxi) fenil)-3,5-dioxo -2,3,4,5-tetrahidro -1,2,4-triazina-6-carbonitrilo. |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024013198A MX2024013198A (es) | 2018-07-02 | 2021-01-06 | Formas solidas de 2-(3,5-dicloro-4-( (5-isopropil-6-oxo -1,6-dihidropiridazin-3-il) oxi) fenil)-3,5-dioxo -2,3,4,5-tetrahidro -1,2,4-triazina-6-carbonitrilo |
| MX2023009701A MX2023009701A (es) | 2018-07-02 | 2021-01-06 | Formas solidas de 2-(3,5-dicloro-4-( (5-isopropil-6-oxo -1,6-dihidropiridazin-3-il) oxi) fenil)-3,5-dioxo -2,3,4,5-tetrahidro -1,2,4-triazina-6-carbonitrilo. |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20210122740A1 (https=) |
| EP (2) | EP3818057A1 (https=) |
| JP (2) | JP2021530456A (https=) |
| KR (2) | KR102890565B1 (https=) |
| CN (1) | CN112638904A (https=) |
| AR (1) | AR115666A1 (https=) |
| AU (2) | AU2019298236A1 (https=) |
| CA (1) | CA3104860A1 (https=) |
| IL (2) | IL321116A (https=) |
| MX (3) | MX2021000107A (https=) |
| TW (1) | TW202019914A (https=) |
| WO (1) | WO2020010068A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT4406594T (lt) | 2012-09-17 | 2025-12-29 | Madrigal Pharmaceuticals, Inc. | Skydliaukės hormono analogai |
| IL266054B2 (en) | 2016-10-18 | 2023-10-01 | Madrigal Pharmaceuticals Inc | Methods for treating liver disorders or lipid disorders using a THR-BETA agonist |
| US12338206B2 (en) | 2019-02-21 | 2025-06-24 | Nanjing Ruijie Pharma Co., Ltd. | Compounds and their uses as thyroid hormone receptor agonists |
| GEP20247637B (en) | 2019-05-08 | 2024-06-25 | Aligos Therapeutics Inc | Modulators of thr-b and methods of use thereof |
| WO2021063367A1 (zh) * | 2019-09-30 | 2021-04-08 | 苏州科睿思制药有限公司 | 一种Resmetirom晶型及其制备方法和用途 |
| WO2021129465A1 (zh) * | 2019-12-26 | 2021-07-01 | 苏州科睿思制药有限公司 | 一种Resmetirom晶型及其制备方法和用途 |
| US12595254B2 (en) | 2020-09-10 | 2026-04-07 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Crystal form of Resmetirom, preparation method therefor, and use thereof |
| WO2022086894A1 (en) | 2020-10-19 | 2022-04-28 | Teva Pharmaceuticals International Gmbh | Solid state forms of resmetirom |
| KR20230142523A (ko) * | 2021-02-01 | 2023-10-11 | 마드리갈 파마슈티칼스, 인크. | 간 장애 또는 지질 장애의 치료를 위한 로수바스타틴 및 레스메티롬의 치료용 조합 |
| CN114907327A (zh) * | 2021-02-10 | 2022-08-16 | 杭州领业医药科技有限公司 | Resmetirom的晶型及其制备方法和用途 |
| WO2022225827A1 (en) * | 2021-04-21 | 2022-10-27 | Merck Sharp & Dohme Llc | Novel forms of cyclic dinucleotide compounds |
| JP2024544538A (ja) * | 2021-11-11 | 2024-12-03 | ターンズ・ファーマシューティカルズ・インコーポレイテッド | ＴＨＲ－βアゴニストによる肝障害の治療 |
| WO2024263714A1 (en) | 2023-06-22 | 2024-12-26 | Madrigal Pharmaceuticals, Inc. | BIOMARKERS FOR TREATING LIVER DISORDERS WITH THR-β AGONISTS AND RELATED USES |
| WO2025011259A1 (zh) * | 2023-07-07 | 2025-01-16 | 苏州科睿思制药有限公司 | 瑞司美替罗的晶型及其制备方法和用途 |
| CN119613386A (zh) * | 2023-09-14 | 2025-03-14 | 杭州科巢生物科技有限公司 | 一种瑞司美替罗1,4-二氧六环溶剂化合物及其制备方法 |
| WO2025083699A2 (en) | 2023-10-16 | 2025-04-24 | Cipla Limited | Resmetirom polymorphs and process thereof |
| US12377104B1 (en) | 2024-02-06 | 2025-08-05 | Madrigal Pharmaceuticals, Inc. | Methods for treating a fatty liver disease |
| WO2025171032A1 (en) | 2024-02-06 | 2025-08-14 | Madrigal Pharmaceuticals, Inc. | Methods for treating a fatty liver disease |
| WO2025172958A1 (en) * | 2024-02-16 | 2025-08-21 | Metrochem Api Pvt Ltd | Solid state forms of resmetirom |
| WO2025231587A1 (zh) * | 2024-05-06 | 2025-11-13 | 杭州科巢生物科技有限公司 | 一种瑞司美替罗无水晶型ch及其制备方法 |
| WO2026067708A1 (zh) * | 2024-09-30 | 2026-04-02 | 齐鲁制药有限公司 | 瑞司美替罗晶型及其制备方法和用途 |
| WO2026074443A1 (en) | 2024-10-01 | 2026-04-09 | Assia Chemical Industries Ltd. | Solid state forms of resmetirom |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001051919A2 (en) * | 2000-01-07 | 2001-07-19 | Transform Pharmaceuticals, Inc. | High-throughput formation, identification, and analysis of diverse solid-forms |
| PL1919878T3 (pl) * | 2005-07-21 | 2011-03-31 | Hoffmann La Roche | Pochodne pirydazynonu jako agoniści receptora hormonu tarczycy |
| LT4406594T (lt) * | 2012-09-17 | 2025-12-29 | Madrigal Pharmaceuticals, Inc. | Skydliaukės hormono analogai |
| IL266054B2 (en) * | 2016-10-18 | 2023-10-01 | Madrigal Pharmaceuticals Inc | Methods for treating liver disorders or lipid disorders using a THR-BETA agonist |
-
2019
- 2019-07-01 TW TW108123112A patent/TW202019914A/zh unknown
- 2019-07-01 AR ARP190101846A patent/AR115666A1/es unknown
- 2019-07-02 CA CA3104860A patent/CA3104860A1/en active Pending
- 2019-07-02 JP JP2020572517A patent/JP2021530456A/ja active Pending
- 2019-07-02 IL IL321116A patent/IL321116A/en unknown
- 2019-07-02 WO PCT/US2019/040276 patent/WO2020010068A1/en not_active Ceased
- 2019-07-02 KR KR1020217003360A patent/KR102890565B1/ko active Active
- 2019-07-02 EP EP19745399.6A patent/EP3818057A1/en not_active Withdrawn
- 2019-07-02 KR KR1020257038532A patent/KR20250167140A/ko active Pending
- 2019-07-02 EP EP24214548.0A patent/EP4552643A3/en active Pending
- 2019-07-02 US US17/257,070 patent/US20210122740A1/en not_active Abandoned
- 2019-07-02 CN CN201980056826.0A patent/CN112638904A/zh active Pending
- 2019-07-02 AU AU2019298236A patent/AU2019298236A1/en not_active Abandoned
- 2019-07-02 MX MX2021000107A patent/MX2021000107A/es unknown
-
2020
- 2020-12-23 IL IL279700A patent/IL279700A/en unknown
-
2021
- 2021-01-06 MX MX2024013198A patent/MX2024013198A/es unknown
- 2021-01-06 MX MX2023009701A patent/MX2023009701A/es unknown
-
2024
- 2024-05-09 JP JP2024076310A patent/JP2024105460A/ja active Pending
- 2024-11-15 US US18/949,309 patent/US20250074898A1/en active Pending
-
2025
- 2025-01-10 AU AU2025200189A patent/AU2025200189A1/en active Pending
- 2025-08-19 US US19/303,585 patent/US20250368626A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250074898A1 (en) | 2025-03-06 |
| AU2025200189A1 (en) | 2025-01-30 |
| IL279700A (en) | 2021-03-01 |
| TW202019914A (zh) | 2020-06-01 |
| JP2024105460A (ja) | 2024-08-06 |
| WO2020010068A1 (en) | 2020-01-09 |
| CN112638904A (zh) | 2021-04-09 |
| JP2021530456A (ja) | 2021-11-11 |
| EP3818057A1 (en) | 2021-05-12 |
| EP4552643A3 (en) | 2025-07-02 |
| MX2023009701A (es) | 2023-08-29 |
| US20250368626A1 (en) | 2025-12-04 |
| AU2019298236A1 (en) | 2021-01-21 |
| KR102890565B1 (ko) | 2025-11-24 |
| IL321116A (en) | 2025-07-01 |
| CA3104860A1 (en) | 2020-01-09 |
| US20210122740A1 (en) | 2021-04-29 |
| KR20250167140A (ko) | 2025-11-28 |
| KR20210027454A (ko) | 2021-03-10 |
| AR115666A1 (es) | 2021-02-10 |
| EP4552643A2 (en) | 2025-05-14 |
| MX2024013198A (es) | 2024-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021000107A (es) | Formas sólidas de 2-(3,5-dicloro-4-((5-isopropil-6-oxo-1,6-dihidro piridazin-3-il)oxi)fenil)-3,5-dioxo-2,3,4,5-tetrahidro-1,2,4-tria zin-6-carbonitrilo. | |
| CL2017000705A1 (es) | Nuevos compuestos | |
| CL2022000027A1 (es) | Compuestos antagonistas de pcsk9. (divisional de solicitud 202003257). | |
| CL2019001340A1 (es) | Formas cristalinas de un inhibidor de magl. | |
| MX394463B (es) | Métodos para tratar trastornos del hígado o trastornos lipídicos con un agonista de thr-beta. | |
| AR095039A1 (es) | Inhibidores quinazolínicos de formas mutadas activantes del receptor del factor de crecimiento epidérmico | |
| CY1120454T1 (el) | Παραγωγα 2,4-θειαζολιδινεδιονης στη θεραπεια διαταραχων του κεντρικου νευρικου συστηματος | |
| MX2018008815A (es) | Inhibidores de tirosina quinasa de bruton. | |
| AR111469A1 (es) | Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma | |
| CL2019000573A1 (es) | Composiciones para comprimidos. | |
| AR107456A1 (es) | Inhibidor de pde1 | |
| UY37517A (es) | Métodos de síntesis de compuestos tiazoles sustituidos | |
| EA201992147A1 (ru) | Ингибиторы тирозинкиназы брутона | |
| AR083417A1 (es) | Composiciones farmaceuticas que contienen un dgat1 inhibidor | |
| EP3874096A4 (en) | WEAR ARRANGEMENT | |
| CL2021000797A1 (es) | Una ayuda para la deposición de fluidos agrícolas. | |
| CL2021002108A1 (es) | Desinfectante endoscopico mejorado | |
| AR116951A1 (es) | Sales cristalinas de un inhibidor de calicreína plasmática | |
| MX2018004979A (es) | Compuesto piranodipiridinico. | |
| AR104935A1 (es) | Formas cristalinas de un inhibidor de histona deacetilasa | |
| ECSP22046595A (es) | Procesos e intermediario para la preparaci?n de oxetan-2-ilmetanamina | |
| PE20251116A1 (es) | Miembro de desgaste para un agitador de molino vertical | |
| AR110998A1 (es) | Inhibidores de la tirosina cinasa de bruton | |
| EP3350846A4 (en) | Multi-step separation of zinc oxide on gallium nitride | |
| CL2019002704A1 (es) | Nuevos métodos para el tratamiento de la esclerosis múltiple. |